Copertina

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Raj Vuppalanchi, Jay H. Hoofnagle, Don C. Rockey, Herbert L. Bonkovsky, Yi‐Ju Li, Dina Halegoua‐DeMarzio, Robert J. Fontana, Christopher Koh, Joseph Odin, Huiman Barnhart
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
di: Einar S. Björnsson
Pubblicazione: (2025)

Reply: Herbal‐Induced Liver Injury Identification and Prevention
di: Dina Halegoua‐DeMarzio, et al.
Pubblicazione: (2024)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Lauren Holtslander, et al.
Pubblicazione: (2025)

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience
di: Harish Gopalakrishna, et al.
Pubblicazione: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
di: David Mehdi Asgher Niazi, et al.
Pubblicazione: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
di: Gina Choi, et al.
Pubblicazione: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
di: Terry Cheuk‐Fung Yip, et al.
Pubblicazione: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
di: Juan Macias, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
di: Eunice Yewon Lee, et al.
Pubblicazione: (2024)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
di: Simone Chin, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply
di: Mattias Mandorfer, et al.
Pubblicazione: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
di: Ryan Yanzhe Lim, et al.
Pubblicazione: (2026)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
di: Sheila L. Noon, et al.
Pubblicazione: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
di: David Tornai, et al.
Pubblicazione: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
di: Irene Spinelli, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)